{"id":"ivermectin","brandName":"Stromectol","genericName":"ivermectin","companyId":"merck","companyName":"Merck & Co.","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Adenosine receptor A3, Multidrug resistance protein 1, Neuronal acetylcholine receptor subunit alpha-7","drugClass":"Antiparasitic [EPC]"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"728 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"635 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"588 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"484 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"463 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"445 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"374 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"286 reports"},{"date":"","signal":"OCULAR HYPERAEMIA","source":"FDA FAERS","actionTaken":"255 reports"},{"date":"","signal":"COMA","source":"FDA FAERS","actionTaken":"246 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Pruritus","drugRate":"27.5%","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"22.6%","severity":"common","organSystem":""},{"effect":"Skin involvement (edema, papular, pustular, urticarial rash)","drugRate":"22.7%","severity":"common","organSystem":""},{"effect":"Inguinal lymph node enlargement","drugRate":"12.6%","severity":"common","organSystem":""},{"effect":"Inguinal lymph node tenderness","drugRate":"13.9%","severity":"common","organSystem":""},{"effect":"Axillary lymph node enlargement","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Arthralgia/synovitis","drugRate":"9.3%","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"3.5%","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"3.2%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"2.8%","severity":"common","organSystem":""},{"effect":"Pruritus (strongyloidiasis)","drugRate":"2.8%","severity":"common","organSystem":""},{"effect":"Cervical lymph node enlargement","drugRate":"5.3%","severity":"common","organSystem":""},{"effect":"Limbitis","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"1.8%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"1.8%","severity":"common","organSystem":""},{"effect":"Facial edema","drugRate":"1.2%","severity":"common","organSystem":""},{"effect":"Orthostatic hypotension","drugRate":"1.1%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"0.9%","severity":"common","organSystem":""},{"effect":"Asthenia/fatigue","drugRate":"0.9%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"0.9%","severity":"common","organSystem":""}],"contraindications":["Infection by Loa loa","Liver function tests abnormal"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Anterior uveitis","drugRate":"","severity":"serious"},{"effect":"Chorioretinitis/choroiditis","drugRate":"","severity":"serious"},{"effect":"Keratitis","drugRate":"","severity":"serious"},{"effect":"Leukopenia","drugRate":"","severity":"serious"},{"effect":"Anemia","drugRate":"","severity":"serious"},{"effect":"Elevation in ALT/AST","drugRate":"2%","severity":"serious"},{"effect":"Decrease in leukocyte count","drugRate":"3%","severity":"serious"}]},"trials":["NCT04407130","NCT05500326","NCT00994422","NCT02046200","NCT04108897","NCT00790998","NCT04446104","NCT04726969","NCT04723459","NCT04523831","NCT03286101","NCT06918665","NCT03177993","NCT03876262","NCT05750043","NCT04041453","NCT03257943","NCT04714515","NCT02616250","NCT02568098","NCT04460547","NCT04729140","NCT02795117","NCT04106726","NCT01493947","NCT03337490","NCT04124250","NCT04429711","NCT04668469","NCT01213576","NCT05198947","NCT04681053","NCT06557603","NCT03576313","NCT05045937","NCT04703205","NCT04944082","NCT01080989","NCT00921154","NCT04447235","NCT07396714","NCT04527211","NCT06184399","NCT04374019","NCT05040724","NCT01903057","NCT04410406","NCT04435587","NCT05082753","NCT05056883"],"indications":{"approved":[{"name":"Infection by Onchocerca volvulus","diseaseId":"infection-by-onchocerca-volvulus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection by Strongyloides","diseaseId":"infection-by-strongyloides","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Method of Use","number":"9233118","applicant":"GALDERMA LABORATORIES LP","territory":"US","tradeName":"SOOLANTRA","expiryDate":"2034-03-13"},{"type":"Method of Use","number":"9089587","applicant":"GALDERMA LABORATORIES LP","territory":"US","tradeName":"SOOLANTRA","expiryDate":"2034-03-13"},{"type":"Method of Use","number":"9233117","applicant":"GALDERMA LABORATORIES LP","territory":"US","tradeName":"SOOLANTRA","expiryDate":"2034-03-13"},{"type":"Method of Use","number":"9782425","applicant":"GALDERMA LABORATORIES LP","territory":"US","tradeName":"SOOLANTRA","expiryDate":"2034-03-13"},{"type":"Method of Use","number":"10206939","applicant":"GALDERMA LABORATORIES LP","territory":"US","tradeName":"SOOLANTRA","expiryDate":"2034-03-13"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT04407130","phase":"Phase 2","title":"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","isPivotal":false,"enrollment":72,"indication":"COVID-19 Patients","completionDate":"2020-11-20"},{"nctId":"NCT05500326","phase":"Phase 2","title":"Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","isPivotal":false,"enrollment":120,"indication":"Scabies; Itch, Scabies","completionDate":"2026-06"},{"nctId":"NCT00994422","phase":"Phase 2","title":"A Double-Blind Randomized Study to Compare the Safety, Local Tolerability and Efficacy of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infes","status":"COMPLETED","sponsor":"Topaz Pharmaceuticals Inc","isPivotal":false,"enrollment":264,"indication":"Head Lice","completionDate":"2009-12"},{"nctId":"NCT02046200","phase":"Phase 1","title":"Repositioning Ivermectin for the Treatment of Alcohol Use Disorders","status":"COMPLETED","sponsor":"University of California, Los Angeles","isPivotal":false,"enrollment":11,"indication":"Alcohol Use Disorder","completionDate":"2015-03"},{"nctId":"NCT04108897","phase":"EARLY/Phase 1","title":"Analysis of the Microbiome in Rosacea","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":150,"indication":"Rosacea","completionDate":"2027-09"},{"nctId":"NCT00790998","phase":"Phase 3","title":"A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus","status":"COMPLETED","sponsor":"Medicines Development for Global Health","isPivotal":true,"enrollment":1497,"indication":"Onchocerciasis","completionDate":"2012-05"},{"nctId":"NCT04446104","phase":"Phase 3","title":"A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)","status":"COMPLETED","sponsor":"National University Hospital, Singapore","isPivotal":true,"enrollment":4257,"indication":"Covid-19","completionDate":"2020-08-31"},{"nctId":"NCT04726969","phase":"Phase 3","title":"Efficacy and Safety of Combination Moxidectin and Albendazole, Ivermectin and Albendazole and Albendazole Alone in Adolescents and Adults Infected With Trichuris Trichiura: a Randomized Controlled Tri","status":"COMPLETED","sponsor":"Jennifer Keiser","isPivotal":true,"enrollment":255,"indication":"Trichuriasis, Ascariasis","completionDate":"2021-09-09"},{"nctId":"NCT04723459","phase":"NA","title":"Nano-Ivermectin Impregnated Masks Versus Ordinary Surgical Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff","status":"UNKNOWN","sponsor":"South Valley University","isPivotal":false,"enrollment":150,"indication":"Covid-19","completionDate":"2021-03-28"},{"nctId":"NCT04523831","phase":"Phase 3","title":"A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care","status":"COMPLETED","sponsor":"Dhaka Medical College","isPivotal":true,"enrollment":400,"indication":"Covid19","completionDate":"2020-09-10"},{"nctId":"NCT03286101","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial On The Efficacy And Safety Of Topical 0.5% Ivermectin Lotion For The Treatment Of Head Lice Infestation Among Filipino Children Age 3 Year","status":"COMPLETED","sponsor":"United Laboratories","isPivotal":false,"enrollment":120,"indication":"Pediculosis Capitis","completionDate":"2017-11-09"},{"nctId":"NCT06918665","phase":"Phase 1","title":"HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation","status":"SUSPENDED","sponsor":"Murdoch Childrens Research Institute","isPivotal":false,"enrollment":52,"indication":"Scabies","completionDate":"2027-08-01"},{"nctId":"NCT03177993","phase":"NA","title":"Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitte","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":4773,"indication":"Lymphatic Filariases, Scabies","completionDate":"2019-10-24"},{"nctId":"NCT03876262","phase":"Phase 3","title":"A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medicines Development for Global Health","isPivotal":true,"enrollment":323,"indication":"Onchocerciasis","completionDate":"2026-01-01"},{"nctId":"NCT05750043","phase":"N/A","title":"Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan, a Three-year Prospective Study","status":"COMPLETED","sponsor":"Universiteit Antwerpen","isPivotal":false,"enrollment":17000,"indication":"Onchocerciasis, Epilepsy","completionDate":"2023-02-19"},{"nctId":"NCT04041453","phase":"Phase 2","title":"Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients","status":"COMPLETED","sponsor":"Alejandro Krolewiecki","isPivotal":false,"enrollment":176,"indication":"Trichuris Infection, Helminthiasis","completionDate":"2020-03-07"},{"nctId":"NCT03257943","phase":"Phase 1","title":"A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Ivermectin Lotion, 0.5% in the Treatment of Subjects With Active Infestation With Head Lice and Their Ova","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","isPivotal":false,"enrollment":413,"indication":"Lice; Head Lice","completionDate":"2017-08-18"},{"nctId":"NCT04714515","phase":"N/A","title":"Using Montelukast to Treat the Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","status":"COMPLETED","sponsor":"University of Sargodha","isPivotal":false,"enrollment":150,"indication":"Covid19, SARS-CoV-2 Infection","completionDate":"2020-04-20"},{"nctId":"NCT02616250","phase":"Phase 4","title":"Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","isPivotal":false,"enrollment":190,"indication":"Rosacea","completionDate":"2016-09"},{"nctId":"NCT02568098","phase":"Phase 1","title":"Open-Label Study to Evaluate Safety, Tolerability, Potential Pharmacokinetic Interactions and Mosquito-Lethal Effects of Orally Administered Ivermectin, Primaquine, Dihydroartemisinin-Piperaquine, and","status":"COMPLETED","sponsor":"University of Oxford","isPivotal":false,"enrollment":16,"indication":"Drug Combination, Pharmacokinetics","completionDate":"2016-12"},{"nctId":"NCT04460547","phase":"N/A","title":"Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study","status":"UNKNOWN","sponsor":"Qassim University","isPivotal":false,"enrollment":200,"indication":"COVID-19","completionDate":"2020-09-20"},{"nctId":"NCT04729140","phase":"Phase 4","title":"A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospit","status":"UNKNOWN","sponsor":"Max Health, Subsero Health","isPivotal":false,"enrollment":150,"indication":"Covid19","completionDate":"2022-03-28"},{"nctId":"NCT02795117","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Padagis LLC","isPivotal":true,"enrollment":486,"indication":"Rosacea","completionDate":"2017-02"},{"nctId":"NCT04106726","phase":"Phase 3","title":"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, COMPARING IVERMECTIN CREAM 1% (ZYDUS WORLDWIDE DMCC) TO SOOLANTRA® (GALDERMA LABORATORIES, L.P.) AND BOTH ACTIVE TRE","status":"COMPLETED","sponsor":"Zydus Worldwide DMCC","isPivotal":true,"enrollment":525,"indication":"Facial Rosacea","completionDate":"2020-08-04"},{"nctId":"NCT01493947","phase":"Phase 3","title":"Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.","status":"COMPLETED","sponsor":"Galderma R&D","isPivotal":true,"enrollment":962,"indication":"Papulopustular Rosacea","completionDate":"2013-12"},{"nctId":"NCT03337490","phase":"Phase 3","title":"A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion i","status":"COMPLETED","sponsor":"Mayne Pharma International Pty Ltd","isPivotal":true,"enrollment":296,"indication":"Head Lice","completionDate":"2017-12-18"},{"nctId":"NCT04124250","phase":"N/A","title":"When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","isPivotal":false,"enrollment":12930,"indication":"Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis","completionDate":"2024-01-01"},{"nctId":"NCT04429711","phase":"NA","title":"Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled T","status":"UNKNOWN","sponsor":"Sheba Medical Center","isPivotal":false,"enrollment":100,"indication":"COVID-19","completionDate":"2020-10-31"},{"nctId":"NCT04668469","phase":"NA","title":"Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","status":"COMPLETED","sponsor":"Benha University","isPivotal":false,"enrollment":600,"indication":"Covid19","completionDate":"2020-10-30"},{"nctId":"NCT01213576","phase":"NA","title":"Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study","status":"TERMINATED","sponsor":"London School of Hygiene and Tropical Medicine","isPivotal":false,"enrollment":70,"indication":"Lymphatic Filariasis","completionDate":"2012-02"},{"nctId":"NCT05198947","phase":"NA","title":"Better Disease Control by Multidrug Regimen in Scabies: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","isPivotal":false,"enrollment":212,"indication":"Scabies","completionDate":"2018-07"},{"nctId":"NCT04681053","phase":"Phase 3","title":"Efficacy and Safety of Inhaled Ivermectin in the Treatment of SARS-COV-2 (COVID-19)","status":"UNKNOWN","sponsor":"Mansoura University","isPivotal":true,"enrollment":80,"indication":"COVID-19","completionDate":"2021-12-31"},{"nctId":"NCT06557603","phase":"Phase 1","title":"Single Dose Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream in Healthy Adult Human Subjects","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","isPivotal":false,"enrollment":44,"indication":"Rosacea","completionDate":"2024-07-22"},{"nctId":"NCT03576313","phase":"Phase 3","title":"Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","isPivotal":true,"enrollment":4939,"indication":"Malaria","completionDate":"2021-07-31"},{"nctId":"NCT05045937","phase":"N/A","title":"Ivermectin Will be Used as an Outpatient Treatment Option for COVID-19 Patients.","status":"UNKNOWN","sponsor":"Patrick Robinson","isPivotal":false,"enrollment":1000,"indication":"Covid19, COVID-19 Pneumonia","completionDate":"2024-05-01"},{"nctId":"NCT04703205","phase":"Phase 2","title":"A Placebo-controlled, Randomized, Double-blind Study in COvid-19 Patients With iveRmectin; An inVEstigator iniTiaTEd Trial","status":"UNKNOWN","sponsor":"Kitasato University","isPivotal":false,"enrollment":214,"indication":"Covid19","completionDate":"2022-05-31"},{"nctId":"NCT04944082","phase":"Phase 4","title":"Remdesivir Versus Remdesivir- Ivermectin Combination Therapy in Severe and Critically Ill Covid-19","status":"UNKNOWN","sponsor":"Assiut University","isPivotal":false,"enrollment":60,"indication":"Covid19","completionDate":"2021-12-31"},{"nctId":"NCT01080989","phase":"NA","title":"The Sero-prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","isPivotal":false,"enrollment":1477,"indication":"Flavivirus Infection, Alphavirus Infections","completionDate":"2011-12"},{"nctId":"NCT00921154","phase":"Phase 1","title":"A Single-dose, Randomised, Crossover Study to Compare the Rate and Extent of Absorption of Two Formulations of Ivermectin in Healthy, Fasting Male and Female Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","isPivotal":false,"enrollment":24,"indication":"Healthy","completionDate":"2005-09"},{"nctId":"NCT04447235","phase":"Phase 2","title":"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19","status":"TERMINATED","sponsor":"Instituto do Cancer do Estado de São Paulo","isPivotal":false,"enrollment":77,"indication":"Cancer, COVID","completionDate":"2022-06-30"},{"nctId":"NCT07396714","phase":"EARLY/Phase 1","title":"Evaluation of the Efficacy & Safety of Topical Ivermectin Alone or in Combination With Microneedling as Novel Therapeutic Options for Cutaneous Non-genital Warts Versus Topical Salicylic Acid ؛ Random","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","isPivotal":false,"enrollment":88,"indication":"Warts","completionDate":"2027-06-01"},{"nctId":"NCT04527211","phase":"Phase 3","title":"Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic: A Randomized Clinical Controled Trial","status":"UNKNOWN","sponsor":"Javeriana University","isPivotal":true,"enrollment":550,"indication":"Covid19, Healthcare Worker Patient Transmission","completionDate":"2020-12-16"},{"nctId":"NCT06184399","phase":"Phase 2","title":"Efficacy, Safety and Acceptability of Ascending Doses of Ivermectin in Combination With Albendazole for Trichuris Trichiura Infections in Preschool-aged Children: a Single-blind Randomised Controlled ","status":"COMPLETED","sponsor":"Jennifer Keiser","isPivotal":false,"enrollment":260,"indication":"Trichuriasis, Ascariasis","completionDate":"2024-08-09"},{"nctId":"NCT04374019","phase":"Phase 2","title":"Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Susanne Arnold","isPivotal":false,"enrollment":13,"indication":"COVID, Sars-CoV2","completionDate":"2022-01-12"},{"nctId":"NCT05040724","phase":"Phase 3","title":"Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 on the Time to Negativation of the SARS-COV-2 Viral Load Determinated by RT-PCR","status":"UNKNOWN","sponsor":"Raincy Montfermeil Hospital Group","isPivotal":true,"enrollment":200,"indication":"To Assess the Reduction in the Viral Load of SARS-CoV-2 in Patients Receiving Ivermectin Compared to Those Receiving Standard Care","completionDate":"2022-06"},{"nctId":"NCT01903057","phase":"Phase 4","title":"AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and","status":"WITHDRAWN","sponsor":"Emory University","isPivotal":false,"enrollment":0,"indication":"Trachoma, Lymphatic Filariasis","completionDate":"2014-07"},{"nctId":"NCT04410406","phase":"Phase 3","title":"A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":true,"enrollment":164,"indication":"Lymphatic Filariasis","completionDate":"2024-10-01"},{"nctId":"NCT04435587","phase":"Phase 4","title":"Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir/ Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Af","status":"UNKNOWN","sponsor":"Mahidol University","isPivotal":false,"enrollment":80,"indication":"Asymptomatic Infections, SARS-CoV2 Infection","completionDate":"2021-11"},{"nctId":"NCT05082753","phase":"Phase 1","title":"Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","isPivotal":false,"enrollment":50,"indication":"Anthelmintic Agent","completionDate":"2020-12-21"},{"nctId":"NCT05056883","phase":"Phase 3","title":"A Phase III Confirmatory Study of K-237-Multi-regional, Multi-center, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Mild COVID-19","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","isPivotal":true,"enrollment":1030,"indication":"Covid19","completionDate":"2022-08-26"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$4.0853/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,491","description":"IVERMECTIN 1% CREAM","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-10-24T00:00:00.000Z","mah":"EDENBRIDGE PHARMS","brand_name_local":null,"application_number":"ANDA204154"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-10-27T00:00:00.000Z","mah":"ARBOR PHARMS LLC","brand_name_local":null,"application_number":"NDA202736"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-03-06T00:00:00.000Z","mah":"PADAGIS ISRAEL","brand_name_local":null,"application_number":"ANDA210225"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-01-22T00:00:00.000Z","mah":"RUBICON RESEARCH","brand_name_local":null,"application_number":"ANDA215922"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-04-07T00:00:00.000Z","mah":"AJANTA PHARMA LTD","brand_name_local":null,"application_number":"ANDA218509"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"9233118","territory":"US","patent_type":"Method of Use","expiry_date":"2034-03-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9089587","territory":"US","patent_type":"Method of Use","expiry_date":"2034-03-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9233117","territory":"US","patent_type":"Method of Use","expiry_date":"2034-03-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9782425","territory":"US","patent_type":"Method of Use","expiry_date":"2034-03-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10206939","territory":"US","patent_type":"Method of Use","expiry_date":"2034-03-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":12,"withResults":5},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ivermectin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:19:09.355790+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:19:09.355729+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:19:15.127412+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:19:08.481916+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ivermectin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:19:15.432659+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:07.378754+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:07.378782+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:07.378787+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:19:17.025709+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glutamate-gated chloride channel modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:16.609113+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6067487/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:16.275676+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA204154","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:07.378790+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:19:19.669634+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL6067487"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}